Abatacept is not recommended to be available as a routine commissioning treatment option for autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation within the criteria set out in the policy document here.

The policy is restricted to adults and children aged 2 years and over in line with licenced indications for abatacept. There is insufficient safety data for use of intravenous abatacept in children under the age of 2 years old.